Disparities in refusal of surgery for gynecologic cancer.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
07 2023
Historique:
received: 28 12 2022
revised: 07 04 2023
accepted: 17 04 2023
medline: 27 6 2023
pubmed: 5 5 2023
entrez: 4 5 2023
Statut: ppublish

Résumé

To identify sociodemographic and clinical factors associated with refusal of gynecologic cancer surgery and to estimate its effect on overall survival. The National Cancer Database was surveyed for patients with uterine, cervical or ovarian/fallopian tube/primary peritoneal cancer treated between 2004 and 2017. Univariate and multivariate logistic regression were used to assess associations between clinico-demographic variables and refusal of surgery. Overall survival was estimated using the Kaplan-Meier method. Trends in refusal over time were evaluated using joinpoint regression. Of 788,164 women included in our analysis, 5875 (0.75%) patients refused surgery recommended by their treating oncologist. Patients who refused surgery were older at diagnosis (72.4 vs 60.3 years, p < 0.001) and more likely Black (OR 1.77 95% CI 1.62-1.92). Refusal of surgery was associated with uninsured status (OR 2.94 95% CI 2.49-3.46), Medicaid coverage (OR 2.79 95% CI 2.46-3.18), low regional high school graduation (OR 1.18 95% CI 1.05-1.33) and treatment at a community hospital (OR 1.59 95% CI 1.42-1.78). Patients who refused surgery had lower median overall survival (1.0 vs 14.0 years, p < 0.01) and this difference persisted across disease sites. Between 2008 and 2017, there was a significant increase in refusal of surgery annually (annual percent change +1.41%, p < 0.05). Multiple social determinants of health are independently associated with refusal of surgery for gynecologic cancer. Given that patients who refuse surgery are more likely from vulnerable, underserved populations and have inferior survival, refusal of surgery should be considered a surgical healthcare disparity and tackled as such.

Identifiants

pubmed: 37141816
pii: S0090-8258(23)00188-9
doi: 10.1016/j.ygyno.2023.04.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

David Samuel (D)

University of Miami, Miller School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology, Miami, FL, United States of America. Electronic address: david.samuel@jhsmiami.org.

Deukwoo Kwon (D)

Icahn School of Medicine at Mount Sinai, Department of Population Health Science and Policy, New York, NY, United States of America.

Marilyn Huang (M)

University of Miami, Miller School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology, Miami, FL, United States of America; Sylvester Comprehensive Cancer Center, Division of Gynecologic Oncology, Miami, FL, United States of America.

Wei Zhao (W)

Sylvester Comprehensive Cancer Center, Biostatistics and Bioinformatics Shared Resource, Miami, FL, United States of America.

Molly Roy (M)

University of Miami, Miller School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology, Miami, FL, United States of America.

Angel Tabuyo-Martin (A)

University of Miami, Miller School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology, Miami, FL, United States of America.

John Siemon (J)

University of Miami, Miller School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology, Miami, FL, United States of America.

Matthew P Schlumbrecht (MP)

University of Miami, Miller School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology, Miami, FL, United States of America; Sylvester Comprehensive Cancer Center, Division of Gynecologic Oncology, Miami, FL, United States of America.

J Matt Pearson (JM)

University of Miami, Miller School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology, Miami, FL, United States of America; Sylvester Comprehensive Cancer Center, Division of Gynecologic Oncology, Miami, FL, United States of America.

Abdulrahman K Sinno (AK)

University of Miami, Miller School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Gynecologic Oncology, Miami, FL, United States of America; Sylvester Comprehensive Cancer Center, Division of Gynecologic Oncology, Miami, FL, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH